½ÃÀ庸°í¼­
»óǰÄÚµå
1493252

ÇコÄɾî¿ë Ư±Ç ¾×¼¼½º °ü¸® ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : ¼Ö·ç¼Ç À¯Çüº°, µµÀÔº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2024-2030³â)

Privileged Access Management In Healthcare Market Size, Share & Trends Analysis Report By Solution Type, By Deployment (Cloud, On-Premise, Hybrid), By End-use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÇコÄɾî¿ë Ư±Ç ¾×¼¼½º °ü¸® ½ÃÀå ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ ÇコÄɾî¿ë Ư±Ç ¾×¼¼½º °ü¸® ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 4¾ï 8,810¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024-2030³âÀÇ CAGRÀº 11.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

Ư±Ç ¾×¼¼½º °ü¸®(Privileged Access Management, PAM)´Â ¾ÇÀÇÀûÀÎ »ç¿ëÀÚ³ª ±ÇÇÑÀÌ ¾ø´Â »ç¿ëÀÚÀÇ Á¢±ÙÀ¸·ÎºÎÅÍ µðÁöÅÐ ÀÚ»êÀ» º¸È£Çϱâ À§ÇÑ º¸¾È ¼Ö·ç¼ÇÀ» ±â¾÷¿¡ Á¦°øÇÏ´Â °Í°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ±ÇÇÑÀÌ ºÎ¿©µÈ °èÁ¤À» ¸ð´ÏÅ͸µÇÏ°í °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

PAM ¼Ö·ç¼ÇÀ» ÅëÇØ ±â¾÷Àº Çã°¡µÈ »ç¿ëÀÚ¸¸ ¼ÒÁßÇÑ µðÁöÅÐ Àڻ꿡 Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© º¸¾È Ä§ÇØ ¹× »çÀ̹ö °ø°ÝÀÇ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î »çÀ̹ö °ø°ÝÀ¸·ÎºÎÅÍ Á¶Á÷À» º¸È£ÇÏ´Â CyberArk´Â 2023³â 3¿ù Àεµ ÇÏÀ̵¥¶ó¹Ùµå¿¡ »õ·Î¿î »ç¹«½ÇÀ» °³¼³Çß½À´Ï´Ù. ÀÌ »ç¹«½ÇÀº »ç¶÷µéÀÇ ¿Â¶óÀÎ ½Å¿ø º¸¾ÈÀ» À§ÇÑ »õ·Î¿î Àü·«°ú ¼Ö·ç¼ÇÀ» ¿¬±¸ÇÏ°í °³¹ßÇÏ´Â µ¥ »ç¿ëµÉ ¿¹Á¤ÀÔ´Ï´Ù. ¶ÇÇÑ ¸¶ÄÉÆÃ ¹× °í°´ Áö¿øÀ» À§ÇÑ Æ¯º° ÆÀµµ ±¸¼ºµÉ ¿¹Á¤ÀÔ´Ï´Ù. ÀÌ »õ·Î¿î »ç¹«½ÇÀº CyberArk°¡ Àεµ °í°´°ú ÆÄÆ®³Ê¿¡°Ô ´õ ³ªÀº ¼­ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù.

º¥´õ¿¡ ƯȭµÈ PAM ¼Ö·ç¼ÇÀ» µµÀÔÇÏ¸é Æ¯±Ç °èÁ¤ÀÇ Á¢±Ù ±ÇÇÑÀ» È¿À²ÀûÀ¸·Î °ü¸®Çϰí, Ư±Ç °èÁ¤ÀÇ È°µ¿À» »çÀü¿¡ ¸ð´ÏÅ͸µ ¹× Á¦¾îÇÏ¿© È¿°úÀûÀ¸·Î À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº »ýü ÀνÄ, QRÄÚµå ¹× ±âŸ ºñ¹Ð¹øÈ£°¡ ÇÊ¿ä ¾ø´Â ÀÎÁõ ¿ä¼Ò¸¦ ÅëÇÑ ´Ù´Ü°è ÀÎÁõ(MFA)À» Áö¿øÇϸ鼭 º¥´õ¿¡°Ô ºü¸£°í ¾ÈÀüÇÏ¸ç Æí¸®ÇÑ ¾×¼¼½º¸¦ Á¦°øÇÕ´Ï´Ù. Ÿ»ç PAM ¼Ö·ç¼ÇÀº VPN Ŭ¶óÀ̾ðÆ®, ºñ¹Ð¹øÈ£, ¿¡ÀÌÀüÆ® µîÀÇ ·¹°Å½Ã Á¢±Ù ¹æ½Ä¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ¾ø¾Ö°í °ü·Ã À§ÇèÀ» ÁÙÀÔ´Ï´Ù. ¶ÇÇÑ PAM ¼Ö·ç¼ÇÀº Ư±Ç ¼¼¼Ç °ü¸®, ½Ç½Ã°£ À§Çù ŽÁö, »õ·Î¿î »çÀ̹ö À§ÇùÀ» ¹æ¾îÇϱâ À§ÇÑ ÀÚµ¿ ´ëÀÀ ±â´É µî °í±Þ ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÇ·á ±â°üÀÌ Á¾ÀÌ ±â¹Ý ½Ã½ºÅÛ¿¡¼­ ÀüÀÚ ÀÇ·á ±â·Ï(EHR) ¹× ±âŸ µðÁöÅÐ Ç÷§ÆûÀ¸·Î ÀüȯÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ±â¹Ð µ¥ÀÌÅÍ Àڻ꿡 ´ëÇÑ Æ¯±Ç ¾×¼¼½º¸¦ ¾ÈÀüÇÏ°Ô °ü¸®ÇØ¾ß ÇÒ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ȯÀÚ ±â·ÏÀÇ µðÁöÅÐÈ­´Â º´·Â, Ä¡·á °èȹ, Áø´Ü °Ë»ç °á°ú, û±¸ Á¤º¸ µî ¹æ´ëÇÑ ¾çÀÇ °³ÀÎ °Ç°­ Á¤º¸(PHI)°¡ ÀüÀÚÀûÀ¸·Î ÀúÀåµÈ´Ù´Â °ÍÀ» ÀǹÌÇÕ´Ï´Ù. ÀÌ·¯ÇÑ µðÁöÅÐÈ­´Â ¹«´Ü Á¢±Ù, µ¥ÀÌÅÍ À¯Ãâ, »çÀ̹ö À§ÇùÀÇ À§ÇèÀ» Áõ°¡½Ãŵ´Ï´Ù.

PAM ¼Ö·ç¼ÇÀº Áß¾Ó ÁýÁᫎ ¾×¼¼½º Á¦¾î, ÀÎÁõ ¸ÞÄ¿´ÏÁò, ±ÇÇÑ ÀÖ´Â ¼¼¼Ç ¸ð´ÏÅ͸µÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ º¸¾È ¹®Á¦¸¦ ÇØ°áÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, PAM ¼Ö·ç¼ÇÀ» µµÀÔÇÔÀ¸·Î½á ÀÇ·á ±â°üÀº ÃÖ¼Ò ±ÇÇÑ ¾×¼¼½º ¿øÄ¢À» ±¸ÇöÇÏ°í ½ÂÀÎµÈ »ç¿ëÀÚ¸¸ ¹Î°¨ÇÑ È¯ÀÚ µ¥ÀÌÅÍ¿Í Áß¿ä ½Ã½ºÅÛ¿¡ Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ½ÂÀÎµÈ »ç¿ëÀÚ¸¸ ¹Î°¨ÇÑ È¯ÀÚ µ¥ÀÌÅÍ ¹× Áß¿ä ½Ã½ºÅÛ¿¡ Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PAM ¼Ö·ç¼ÇÀº MFA ¹× ¼¼¼Ç ±â·Ï°ú °°Àº ±â´ÉÀ» Á¦°øÇÏ¿© ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ HIPAA(Health Insurance Portability and Accountability Act, ÀǷẸÇè »óÈ£¿î¿ë¼º ¹× Ã¥ÀÓ¿¡ °üÇÑ ¹ý·ü)¿Í °°Àº ±ÔÁ¦ ¿ä°ÇÀ» ÁؼöÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. HIPAA´Â PHIÀÇ ±â¹Ð¼º, ¹«°á¼º ¹× °¡¿ë¼ºÀ» º¸È£Çϱâ À§ÇØ ¾ö°ÝÇÑ º¸¾È Á¶Ä¡¸¦ ¿ä±¸Çϰí ÀÖÀ¸¹Ç·Î PAM ¼Ö·ç¼ÇÀº ÇコÄÉ¾î »çÀ̹ö º¸¾È Àü·«¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

ÇコÄɾî¿ë Ư±Ç ¾×¼¼½º °ü¸® ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ¼Ö·ç¼Ç À¯Çüº°·Î´Â Ư±Ç °èÁ¤ ¹× ¼¼¼Ç °ü¸® ¼­ºñ½º(PASM) ºÐ¾ß°¡ 2023³â 38.41%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¹èÄ¡ À¯Çüº°·Î´Â Ŭ¶ó¿ìµå ±â¹Ý ºÎ¹®ÀÌ 2023³â 48.96%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý PAM ¼Ö·ç¼ÇÀº ÀÎÀ§ÀûÀÎ ½Ç¼ö³ª ¿ì¹ßÀûÀÎ µ¥ÀÌÅÍ À¯Ãâ °¡´É¼ºÀ» ÃÖ¼ÒÈ­ÇÏ°í ±ÇÇÑÀÌ ºÎ¿©µÈ »ç¿ëÀÚ¸¸ ±â¹Ð ÀÛ¾÷À» ¼öÇàÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© Àü¹ÝÀûÀÎ º¸¾ÈÀ» °­È­ÇÕ´Ï´Ù.
  • ÃÖÁ¾»ç¿ëÀÚº°·Î´Â º´¿ø ¹× Ŭ¸®´Ð ºÐ¾ß°¡ 2023³â 43.15%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â º´¿ø³» µ¥ÀÌÅÍ ÀúÀå ¹× ±â¹Ð Á¤º¸ °ü¸®¸¦ À§ÇÑ Ã·´Ü ±â¼ú µµÀÔÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.
  • ºÏ¹Ì´Â 2023³â 39.0%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº »çÀ̹ö °ø°ÝÀÇ ºóµµ¿Í °íµµÈ­, Ŭ¶ó¿ìµå ±â¹Ý ¼­ºñ½º ¹× »ç¹°ÀÎÅͳÝ(IoT) äÅà Áõ°¡, ÀÌ Áö¿ª¿¡ ´Ù¼ö ½ÃÀå ±â¾÷ÀÌ Á¸ÀçÇϱ⠶§¹®ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Æ¯±Ç ¾×¼¼½º °ü¸® ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • ¸ð½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
    • ½ÃÀå ±âȸ
  • Ư±Ç ¾×¼¼½º °ü¸® ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - PorterÀÇ »ê¾÷ ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå Æ¯±Ç ¾×¼¼½º °ü¸® ½ÃÀå : ¼Ö·ç¼Ç À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

  • ¼Ö·ç¼Ç À¯ÇüÀÇ ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°è Ư±Ç ¾×¼¼½º °ü¸® ½ÃÀå, ÄÄÆ÷³ÍÆ®º° Àü¸Á
  • Ư±Ç ¾îÄ«¿îÆ®¡¤¼¼¼Ç °ü¸® ¼­ºñ½º(PASM)
  • Ư±Ç ½Â°Ý¡¤À§ÀÓ °ü¸®(PEDM)
  • ºñ¹Ð °ü¸®
  • ±âŸ ¼Ö·ç¼Ç

Á¦5Àå Æ¯±Ç ¾×¼¼½º °ü¸® ½ÃÀå : µµÀÔ À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

  • µµÀÔ À¯ÇüÀÇ ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°è Ư±Ç ¾×¼¼½º °ü¸® ½ÃÀå, µµÀÔ À¯Çüº° Àü¸Á
  • Ŭ¶ó¿ìµå ±â¹Ý
  • ¿ÂÇÁ·¹¹Ì½º
  • ÇÏÀ̺긮µå

Á¦6Àå Æ¯±Ç ¾×¼¼½º °ü¸® ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ÃÖÁ¾ ¿ëµµº° ¼¼°è Ư±Ç ¾×¼¼½º °ü¸® ½ÃÀåÀÇ Àü¸Á
  • º´¿ø¡¤Å¬¸®´Ð
  • »ý¸í°úÇÐ ±â¾÷
  • ÇコÄÉ¾î °áÁ¦
  • ±âŸ ÃÖÁ¾ ¿ëµµ

Á¦7Àå Æ¯±Ç ¾×¼¼½º °ü¸® ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®, ÄÄÆ÷³ÍÆ®º°, ±â´Éº°, µµÀÔ À¯Çüº°, ÃÖÁ¾ ¿ëµµº°

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ¼¼°è Áö¿ª ½ÃÀå ½º³À¼ô
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â :
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷/°æÀï ºÐ·ù
    • À̳뺣ÀÌÅÍ
    • ÁÖ¿ä ÆÇ¸Å ´ë¸®Á¡ ¹× ä³Î ÆÄÆ®³Ê ¸®½ºÆ®
    • ÁÖ¿ä °í°´
    • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
    • ½Ã½ºÄÚ ½Ã½ºÅÛÁî ÁÖ½Äȸ»ç
    • IBM
    • Marubeni Information Systems Co.,Ltd
    • Symantec Corporation
    • Trend Micro Incorporated
    • McAfee, LLC
    • Intel Corporation
    • AO Kaspersky Lab
    • Lockheed Martin Corporation
    • Northrop Grumman
    • Medigate(Claroty)
KSA 24.06.19

Privileged Access Management In Healthcare Market Growth & Trends:

The global privileged access management in healthcare market size is anticipated to reach USD 488.1 million by 2030 and is projected to grow at a CAGR of 11.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. Privileged access management (PAM) is related to providing security solutions for companies to protect their digital assets from being accessed by malicious or unauthorized users. PAM tools assist companies in monitoring and managing privileged accounts.

With PAM solutions, companies can ensure that only authorized users have access to their valuable digital assets, which reduces the risk of security breaches or cyber-attacks. For instance, CyberArk, a company that helps protect organizations from cyberattacks, opened a new office in Hyderabad, India, in March 2023. This office will be used to research and develop new strategies and solutions to help keep people's online identities safe. They will also have a special team that helps with marketing and customer support. This new office will help CyberArk better serve its customers and partners in India.

Implementing a vendor-focused PAM solution enables effective risk mitigation by efficiently managing the privileged account access rights and proactively monitoring & controlling privileged account activity. These solutions provide vendors with fast, secure, and convenient access while supporting Multifactor Authentication (MFA) through biometric authentication, QR codes, and other password-less authentication factors. Third-party PAM solutions eliminate the reliance on legacy approaches, such as VPN clients, passwords, and agents, thereby reducing the associated risks. In addition, PAM solutions offer advanced features such as privileged session management, real-time threat detection, and automated response capabilities to defend against emerging cyber threats. Such factors are expected to drive the market growth over the forecast period.

As healthcare organizations transition from paper-based systems to Electronic Health Records (EHRs) and other digital platforms, there is a corresponding need to secure & manage privileged access to these sensitive data assets. Digitalization of patient records means that a vast volume of Personal Health Information (PHI) is stored electronically, including medical histories, treatment plans, diagnostic test results, and billing information. This digitization increases the risk of unauthorized access, data breaches, and cyber threats.

PAM solutions play a crucial role in addressing these security challenges by providing centralized access controls, authentication mechanisms, and privileged session monitoring. By implementing PAM solutions, healthcare organizations can enforce the least privilege access principles, ensuring that only authorized users have access to sensitive patient data and critical systems.

The PAM solutions offer features such as MFA and session recording, which help healthcare providers comply with regulatory requirements such as the Health Insurance Portability and Accountability Act (HIPAA). HIPAA mandates strict security measures to protect the confidentiality, integrity, and availability of PHI, making PAM solutions essential components of healthcare cybersecurity strategies.

Privileged Access Management In Healthcare Market Report Highlights:

  • Based on solution type, the privileged account and session management services (PASM) segment held market with the largest revenue share of 38.41% in 2023, which can primarily be attributed to factors such as technological advancements and the increasing awareness of telehealth
  • Based on deployment type, the cloud-based segment led the market with the largest revenue share of 48.96% in 2023. Cloud-based PAM solutions enhance overall security by minimizing the likelihood of human error and accidental data breaches, ensuring that only authorized users can execute sensitive tasks
  • Based on end use, the hospitals and clinics segment led the market with the largest revenue share of 43.15% in 2023, driven by factors such as the increasing implementation of advanced technology within hospitals for data storage and management of sensitive information
  • North America dominated the market with the largest revenue share of 39.0% in 2023. The key attributing factors for the market growth are the increasing frequency & sophistication of cyberattacks, the rising adoption of cloud-based services and the Internet of Things (IoT), and presence of numerous market players in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Solution Type
    • 1.1.2. Deployment type
    • 1.1.3. End use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
    • 1.6.3. Volume price analysis (Model 2)
    • 1.6.4. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Solution type outlook
    • 2.2.2. Deployment type outlook
    • 2.2.3. End-use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Privileged Access Management Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
    • 3.2.3. Market Challenges
    • 3.2.4. Market Opportunities
  • 3.3. Privileged Access Management Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & legal landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social & environmental landscape
      • 3.3.2.4. Technological landscape

Chapter 4. Privileged Access Management Market: Solution Type Estimates & Trend Analysis

  • 4.1. Solution Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Privileged Access Management Market, by Component Outlook
    • 4.3.1. Privileged Account And Session Management Services (PASM)
      • 4.3.1.1. Market estimates and forecast, 2018 to 2030 (USD Million)
    • 4.3.2. Privilege Elevation And Delegation Management (PEDM)
      • 4.3.2.1. Market estimates and forecast, 2018 to 2030 (USD Million)
    • 4.3.3. Secrets Management
      • 4.3.3.1. Market estimates and forecast, 2018 to 2030 (USD Million)
    • 4.3.4. Other Solution Type
      • 4.3.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 5. Privileged Access Management Market: Deployment Type Estimates & Trend Analysis

  • 5.1. Deployment Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Privileged Access Management Market, by Deployment Type Outlook
    • 5.3.1. Cloud Based
      • 5.3.1.1. Market estimates and forecast, 2018 to 2030 (USD Million)
    • 5.3.2. On-Premise
      • 5.3.2.1. Market estimates and forecast, 2018 to 2030 (USD Million)
    • 5.3.3. Hybrid
      • 5.3.3.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 6. Privileged Access Management Market: End-use Estimates & Trend Analysis

  • 6.1. End-use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Privileged Access Management Market by End-use Outlook
    • 6.3.1. Hospitals and Clinics
      • 6.3.1.1. Market estimates and forecast, 2018 to 2030 (USD Million)
    • 6.3.2. Life Science Companies
      • 6.3.2.1. Market estimates and forecast, 2018 to 2030 (USD Million)
    • 6.3.3. Healthcare Payers
      • 6.3.3.1. Market estimates and forecast, 2018 to 2030 (USD Million)
    • 6.3.4. Other End Use
      • 6.3.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 7. Privileged Access Management Market: Regional Estimates & Trend Analysis, By Component, By Functionality, By Deployment Type, By End Use

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.6. Denmark
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.8. Norway
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
    • 8.2.1. Innovators
    • 8.2.2. List of key distributors and channel partners
    • 8.2.3. Key customers
    • 8.2.4. Key company market share analysis, 2023
    • 8.2.5. Cisco Systems Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. IBM
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Marubeni Information Systems Co.,Ltd
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Symantec Corporation
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Trend Micro Incorporated
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. McAfee, LLC
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. Intel Corporation
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. AO Kaspersky Lab
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives
    • 8.2.13. Lockheed Martin Corporation
      • 8.2.13.1. Company overview
      • 8.2.13.2. Financial performance
      • 8.2.13.3. Product benchmarking
      • 8.2.13.4. Strategic initiatives
    • 8.2.14. Northrop Grumman
      • 8.2.14.1. Company overview
      • 8.2.14.2. Financial performance
      • 8.2.14.3. Product benchmarking
      • 8.2.14.4. Strategic initiatives
    • 8.2.15. Medigate (Claroty)
      • 8.2.15.1. Company overview
      • 8.2.15.2. Financial performance
      • 8.2.15.3. Product benchmarking
      • 8.2.15.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦